These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2137 related articles for article (PubMed ID: 11732120)

  • 1. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization against poliomyelitis: risk/benefit/cost in a changing context.
    Salk J
    Dev Biol Stand; 1979; 43():151-7. PubMed ID: 230106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral vaccines against poliomyelitis and vaccination-related paralytic poliomyelitis in Germany. Do we need a new immunization strategy?].
    Fescharek R; Arras-Reiter C; Arens ER; Quast U; Maass G
    Wien Med Wochenschr; 1997; 147(19-20):456-61. PubMed ID: 9471843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Problems of prevention and control of poliomyelitis in Poland].
    Mazurowska-Magdzik W; Bucholc B; Janaszek-Seydlitz W; Szkoda T; Magdzik W
    Przegl Epidemiol; 2010; 64(3):341-7. PubMed ID: 20976944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Circulation of the poliovirus in endemic zones with children vaccinated by the oral polio vaccine].
    Gouandjika I; Rakoto Andrianarivelo M; Akoua-Koffi C; Zeller H; Ehouman A; Morvan JM
    Bull Soc Pathol Exot; 2000 Jul; 93(3):198-201. PubMed ID: 11030057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978-93.
    Tulchinsky T; Abed Y; Handsher R; Toubassi N; Acker C; Melnick J
    Isr J Med Sci; 1994; 30(5-6):489-94. PubMed ID: 8034509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
    Shimizu H; Takeda N
    Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polio endgame.
    Minor P
    Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating vaccine derived polio viruses and their impact on global polio eradication.
    Wagner BG; Earn DJ
    Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.